Nymox Pharmaceutical Corp. (NYMX) Stock Quote

Detailed Quote for Nymox Pharmaceutical Corp. (NYMX) 
$ 8.77   -0.05 (-0.57%) Volume: 41.76 k 4:00 PM EST Feb 6, 2012
Today 5d 1m 3m 1y more
Last Price
8.77
Change $
0.05
Change %
0.57%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
8.80
High
8.83
Low
8.61
Prev Close
8.82
Last Trade
2/6/12
Volume
41.76 k
52 Wk Hi
9.89
52 Wk Low
6.00
Market Cap
287.26 m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
32,754,311
EPS (TTM)
-0.32
PE Ratio
N/A
Exchange
NSC
News and Media for Nymox Pharmaceutical Corp.  (NYMX) 
Sector News | Topic News
News for NYMX
Thu, Dec 22, 2011
8:30 AM Nymox Announces New $15 Million Equity Financing Commitment - Globe Newswire
Tue, Nov 22, 2011
12:01 PM Nymox Provides Safety Monitoring Committee Results and Update for Pivotal Phase 3 NX-1207 Trials - Globe Newswire
Mon, Nov 14, 2011
9:53 AM Nymox Reports Third Quarter 2011 Financial Results - Globe Newswire
Fri, Nov 04, 2011
12:00 PM Presentation on Nymox NX-1207 Prostate Drug in Orlando Today at American Urological Association Meeting - Globe Newswire
Mon, Oct 31, 2011
10:45 AM Long Term Results on Nymox NX-1207 BPH Drug Presented at American Urological Association Meeting in New Orleans - Globe Newswire
Wed, Oct 19, 2011
1:16 PM New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19 - Globe Newswire
Tue, Oct 11, 2011
10:00 AM Nymox NX-1207 BPH Drug to be Presented at Orlando Meeting of American Urological Association - Globe Newswire
Tue, Oct 04, 2011
10:05 AM Presentation of Results on Nymox NX-1207 BPH Drug in New Orleans October 28 at Meeting of American Urological Association - Globe Newswire
Mon, Sep 26, 2011
10:07 AM New Peer-Reviewed Publication in Therapeutic Advances in Chronic Disease Features Nymox NX-1207 Drug for BPH - Globe Newswire
Wed, Aug 17, 2011
10:14 AM August 16 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials Indicates Favorable Safety Profile - Globe Newswire
Tue, Aug 16, 2011
12:14 PM Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting October 19 - Globe Newswire
Fri, Aug 12, 2011
10:00 AM Nymox Reports Second Quarter 2011 Financial Results - Globe Newswire
Tue, May 17, 2011
2:30 PM New Positive Data on NX-1207 Presented at Symposium at American Urological Association Annual Meeting - Globe Newswire
Fri, May 13, 2011
10:30 AM Nymox Reports First Quarter 2011 Financial Results - Globe Newswire
Tue, May 10, 2011
12:30 PM Nymox Announces Clinical Trial NX02-0020 - Globe Newswire
Thu, May 05, 2011
11:26 AM Nymox NX-1207 Symposium at American Urological Association Annual Meeting in Washington D.C. Tuesday May 17 at 1:30 p.m. EDT - Globe Newswire
Wed, May 04, 2011
10:45 AM Safety Monitoring Committee Meeting Positive for Nymox Pivotal Phase 3 NX-1207 Trials - Globe Newswire
Wed, Apr 13, 2011
10:30 AM Nymox Announces New Positive Long-Term 39-45 Month Follow-Up Results From NX02-0016 U.S. Study of NX-1207 for BPH - Globe Newswire
Wed, Mar 16, 2011
10:24 AM Nymox Announces Positive New Results in 7 Year Study of NX-1207 for Benign Prostatic Hyperplasia - Globe Newswire
Tue, Mar 15, 2011
10:14 AM Nymox Reports 2010 Financial Results - Globe Newswire
More News for NYMX >>

Tags for Nymox Pharmaceutical Corp.

Research stocks or mutual funds related to Nymox Pharmaceutical Corp. by keywords or tags. Find companies that have a similar focus to NYMX. The keywords below have been associated to NYMX by either user submission or electronic means.

alzheimer's dementia difference between dementia and alzheimers familial alzheimer's alzheimer drug alzheimer treatment early onset alzheimers alzheimer support alzheimer dementia alzheimer statistics causes of alzheimer's early signs of alzheimer's alzheimer's disease research center alzheimers stages of alzheimers statistics on alzheimer's disease alzheimer's support groups alzheimers diagnosis dementia prevention history of alzheimer's disease alzheimer's disease treatment end stage alzheimers stages dementia dementia vs alzheimers alzheimer signs alzheimer's disease prognosis alzheimer prevention alzheimer's drugs diagnosing alzheimer's dementia and alzheimers history of alzheimers alzheimer's disease statistics alzheimer's information alzheimers treatment alzheimer's treatments early onset dementia stages of alzheimer's disease Drugs alzheimer's gifts alzheimer's diseases alzheimers activities alzheimers hereditary alzheimers symptoms alzheimers support alzheimer's association early alzheimer's symptoms familial alzheimer's disease prevent alzheimer's alzheimer's disease facts signs of alzheimer's disease causes of alzheimers

 

NYE - Equity | NYE - ETF | AMX - Equity | AMX - ETF | NSD - Equity | NSD - ETF
NMF - ETF | NMF - Money Market Fund | NMF - Mutual Fund | OTC - Equity | OTO - Equity | OTO - ETF | OTO - Mutual Fund
CNQ - Equity | CBO - Equity | BDM - Equity | TSX - Equity | TSX - ETF | TSX - Mutual Fund | TSV - Equity | TSV - Mutual Fund

Dow Jones Composite Index | Dow Jones Industrial Avg | Dow Jones Transportation Avg | Dow Jones Utiliy Index | NASDAQ 100
Russell 1000 | Russell 2000 | Russell 3000 | Russell Microcap | Russell Midcap | S&P 500 | S&P MidCap 400 | S&P/TSX 60 | S&P/TSX MidCap

Recently Added Symbols   Firms   Find Financial Advisors

Advisors by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

RIAs by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tags: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Insiders: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.

Copyright © 2010 InvestorPoint.com All rights reserved.